Janux Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | 46.3% | 46.3% | -41.8% |
| FY2021 | -8.9% | -8.9% | -8.6% |
| FY2022 | -19.7% | -19.7% | -17.3% |
| FY2023 | -16.9% | -16.9% | -15.3% |
| FY2024 | -6.7% | -6.7% | -6.5% |
| FY2025 | -11.9% | -11.9% | -11.3% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | 46.3% | 46.3% | -41.8% |
| FY2021 | -8.9% | -8.9% | -8.6% |
| FY2022 | -19.7% | -19.7% | -17.3% |
| FY2023 | -16.9% | -16.9% | -15.3% |
| FY2024 | -6.7% | -6.7% | -6.5% |
| FY2025 | -11.9% | -11.9% | -11.3% |